---
document_datetime: 2023-09-21 17:54:11
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/acomplia-epar-procedural-steps-taken-authorisation_en.pdf
document_name: acomplia-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5299882
conversion_datetime: 2025-12-24 20:28:49.721414
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
•

<!-- image -->

Medicinal product no longer authorised 1/2 © EMEA 2006 BACKGROUND INFORMATION ON THE PROCEDURE 1. Submission of the dossier The applicant sanofi-aventis submitted on 25 April 2005 an application for Marketing Authorisation to the European Medicines Agency (EMEA) for ACOMPLIA, through the centralised procedure. The legal basis for this application refers to: Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application. The  application  submitted  is  a  complete  dossier:  composed  of  administrative  information,  complete quality data, non-clinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies). Scientific Advice The applicant did not seek scientific advice at the CHMP. Licensing status: The product was not licensed in any country at the time of submission of the application. The Rapporteur and Co-Rapporteur appointed by the CHMP were: Rapporteur: T. Salmonson Co-Rapporteur: B. van Zwieten-Boot CHMP Peer reviewers: A. Irs, S. Thirstrup 2. Steps taken for the assessment of the product · The application was received by the EMEA on 25 April 2005. · The procedure started on 18 May 2005. · The Rapporteur's first Assessment Report was circulated to all CHMP members on 28 July 2005. The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  28  July 2005. · During  the  meeting  on  12  -  15  September  2005,  the  CHMP  agreed  on  the  consolidated  List  of Questions  to  be  sent  to  the  applicant.  The  final  consolidated  List  of  Questions  was  sent  to  the applicant on 16 September 2005. · The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  17 November 2005. · The  summary  report  of  the  inspection  carried  out  at  the  following  sites:  Emotional  Brain  B.V.Almere (Netherlands) and Karolinska universitetssjukhuset  -  Huddinge  in  Sweden  between  9-11 November, 2005 and 28-29 November, 2005, respectively was issued on 11 January 2006. · The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 2 January 2006. · During the CHMP meeting on 23-26 January 2006, the CHMP agreed on a list of outstanding issues to be addressed in writing and/or in an oral explanation by the applicant. · The applicant submitted the responses to the list of outstanding issues on 13 February 2006. · The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the list of outstanding issues to all CHMP members on 3 March 2006. The applicant submitted additional updated responses to the list of outstanding issues on 10 March 2006.

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

- Medicinal product no longer authorised 2/2 © EMEA 2006 · The Rapporteurs circulated the Updated Joint Assessment Report on the applicant's responses to the list of outstanding issues to all CHMP members on 16 March 2006. · During  the  CHMP  meeting  on  20-23  March  2006,  outstanding  issues  were  addressed  by  the applicant during an oral explanation before the CHMP on 22 March 2006. A new list of outstanding issues was adopted. · The applicant submitted the responses to the second list of outstanding issues on 30 March 2006. · The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the second list of outstanding issues to all CHMP members on 10 April 2006. · During the meeting on 24-27 April 2006, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a Marketing Authorisation to ACOMPLIA on 27 April 2006 . The applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 25 April 2006. · The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the European Commission, which adopted the corresponding Decisions on 19 June 2006.